Cti Molecular Imaging (NASDAQ:CTMI)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Cti Molecular Imaging Charts. Click Here for more Cti Molecular Imaging Charts.](/p.php?pid=staticchart&s=N%5ECTMI&p=8&t=15)
CTI Mirada Solutions Awarded FDA 510(k) Clearance to Market
Scenium(TM) for Analysis of Neurological PET Scans
KNOXVILLE, Tenn., Jan. 18 /PRNewswire-FirstCall/ -- CTI Molecular Imaging,
Inc. (NASDAQ:CTMI), a leading provider of positron emission tomography (PET)
equipment, molecular biomarkers and services, today announced that its
subsidiary CTI Mirada Solutions, has been awarded FDA 510(k) clearance to
market Scenium, an innovative new quantification tool for the analysis of
neurological positron emission tomography (PET) scans.
Scenium display and analysis software has been developed to aid clinicians in
accurate assessment and quantification of dementia and other neurological
diseases. Initially developed for use in PET studies with fluorodeoxyglucose
(FDG), Scenium has the potential to be used with other PET molecular imaging
agents in the future.
The software is organized as a series of workflows, each is specific to a
particular radiopharmaceutical and disease combination. Based on Mirada's
established image fusion techniques, Scenium enables clinicians to compare
patients' brain scans to standard normal scans, highlighting differences in
uptake. Multiple anatomical regions are highlighted for quick assessment of an
image and quantitative comparison with other images and integration into the
current reporting workflow of the imaging center.
The software will be available as a plug-in to a wide variety of viewing
workstations, and also for use on a standard PC.
"Developed in direct response to the rapidly expanding market for
quantification software, Scenium is expected to achieve a widespread install
base during 2005, particularly with the recent approval for reimbursement for
some neurological FDG scans," commented Christian P. Behrenbruch, president of
CTI Mirada Solutions.
Mirada plans to release Scenium during spring 2005, following product
optimization based on current field trials. The software will be distributed by
CTI PETNET, as well as Mirada's OEM/PACS partners.
About CTI Mirada Solutions:
Mirada Solutions Limited, a wholly owned subsidiary of CTI Molecular Imaging,
is a leading developer of software and analytical tools for medical imaging
workstations, OEM imaging platforms and image analysis in pharmaceutical R&D.
Mirada's unique products aid in better detection, diagnosis and management of
disease through the application of powerful algorithms, quantification tools
and image analysis. Additional information is available at
http://www.mirada-solutions.com/
About CTI Molecular Imaging:
CTI Molecular Imaging, Inc. is a leading supplier of products and services for
positron emission tomography (PET), a diagnostic imaging technology used in the
detection and treatment of cancer, cardiac disease and neurological disorders.
Additional information is available at: http://www.ctimi.com/
Certain matters discussed in this press release constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements may be identified by words such as
"believe," "assume," "expect," "anticipate," "intend," "estimate" or similar
expressions, and any other statements that necessarily depend on future events.
Forward-looking statements involve a number of risks and uncertainties and
there can be no assurance that any forward-looking statements will prove to be
accurate. Various factors could cause actual results to differ materially from
those anticipated in the forward-looking statements. CTI undertakes no
obligation to update or revise any forward-looking statements. Further
information regarding risks, uncertainties and other factors that could
adversely affect CTI or cause actual results to differ materially from those
anticipated in forward-looking statements are included in CTI's Annual Report
on Form 10-K for the fiscal year ended September 30, 2004.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995: Statements in this press release regarding CTI Molecular Imaging, Inc.'s
business which are not historical facts are "forward-looking statements" that
involve risks and uncertainties. For a discussion of such risks and
uncertainties, which could cause actual results to differ from those contained
in the forward-looking statements, see "Risk Factors" in the Company's Annual
Report or Form 10-K for the most recently ended fiscal year.
DATASOURCE: CTI Molecular Imaging, Inc.
CONTACT: Lisa Baird of CTI Molecular Imaging, Inc., +1-865-218-2507; or
Clare F. Jones of CTI Mirada Solutions, +44 1865 265500
Web site: http://www.mirada-solutions.com/
http://www.ctimi.com/